ACAD (acadia-pharm.com) Earnings growth in current year
The success of ACADIA Pharmaceuticals (ACAD) is based on the commercial promotion of Daybue and a strict limit on R&D expenditures. Stable demand within the niche of rare neurological pathologies minimizes macroeconomic impact. On GURU.Markets, the year-over-year EPS growth trend demonstrates the effectiveness of psychosis therapy for Parkinson's disease, which guarantees perpetual demand. Meanwhile, the value of -67.70 serves as the baseline indicator for the asset's current yield.
Financial and market metric breakdowns for ACADIA Pharmaceuticals (ACAD)
- current quotes and average value forecast:
- business market valuation indicators:
- book capitalization data:
- debt and solvency information:
All Debt to Shareholders' Equity Ratio ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Capital|Short-Term Debt to Capital acadia-pharm.com|ACAD - Company Debts|Debt to Net Assets Ratio ACADIA Corp|ACAD - Company Long-Term Debt|Company Current Liabilities ACADIA Pharmaceuticals|Quick Ratio acadia-pharm.com
- net income and valuation multiples indicators:
ACAD - Net Profit|Future Profit ACADIA Pharmaceuticals|ACAD - P/E Multiple|Projected Price to Earnings Ratio ACADIA Corp|ACAD - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ACADIA Corp|ACAD - Operating profit before deduction of amortization|Earnings per share for the last four quarters ACADIA Pharmaceuticals|ACAD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months acadia-pharm.com|ACAD - Earnings growth in current year|Expected earnings per share growth for next year ACADIA Pharmaceuticals
- revenue and sales proceeds data:
Basic company analysis:ACADIA Pharma (ACAD)
Year-over-year earnings per share dynamics serve as an indicator of asset monetization efficiency, measuring the percentage change in net income per share relative to the previous year. Analyzing the annual EPS variable allows for an assessment of how successfully ACADIA Pharmaceuticals (ACAD) converts its monopoly in rare disease niches and revenues from unique drugs into real growth in shareholder value.
Main competitors
BIIB - Expected net earnings per share growth this year|NBIX (Neurocrine Biosciences Inc) - Earnings growth in current year|Earnings growth in current year Regencell Corp|Net earnings per share growth this year AXSM (Axsome Therapeutics)|XENE (xenon-pharma.com) - Earnings per share increase in current year|Earnings per share growth in current year Viking Therapeutics, Inc. VKTX|SUPN (Supernus Pharmaceuticals, Inc.) - Earnings per share trend in current year|Catalyst Pharmaceuticals Inc - Earnings growth in current year|Earnings per share increase in current year DNLI (Denali Corp)|HRMY: Earnings growth in current year|biohavenpharma.com (BHVN) - Earnings growth in current year|Earnings per share growth in current year Amylyx Pharmaceuticals, Inc.|TRVI: Earnings per share increase in current year|Earnings per share growth in current year Praxis Medicines (PRAX)|Net earnings per share growth this year Anavex Life Sciences Corp AVXL|Earnings growth in current year CBLL (CeriBell, Inc.)|Earnings growth in current year prothena.com PRTA|Alector Therapeutics - Earnings growth in current year|Annexon Biosciences (ANNX) - Net earnings per share growth this year|OMER: Earnings growth in current year|Earnings per share growth rate in current year Neurogene Therapeutics (NGNE)|Net earnings per share growth this year ACIU|Earnings growth in current year voyagertherapeutics.com|Net earnings per share growth this year NMRA (Neumora Therapeutics, Inc.)|Net earnings per one share growth for the current year SCLX|Earnings growth in current year TVGN (Tevogen Bio Holdings, Inc.)|Expected net earnings per share growth this year Alpha Cognition Inc (ACOG)|Cognition Therapeutics, Inc. - Earnings growth in current year|inhibikase.com (IKT) - Net earnings per share growth this year|SAVA: Earnings growth in current year|Assertio (ASRT) - Earnings growth in current year|Earnings per share growth in current year Coya Therapeutics Inc|Earnings per share growth in current year VTGN|Earnings per share growth in current year Ovid Therapeutics Inc. (OVID)|Expected net earnings per share growth this year acumenpharm.com|Earnings growth in current year CRVO (CervoMed)|Earnings growth in current year Alterity Therapeutics Ltd. ATHE|Clene Nanomedicine - Earnings growth in current year|PepGen Inc. (PEPG) - Net earnings per share growth this year|JUNS: Earnings growth in current year|relmada.com (RLMD) - Earnings growth in current year|ANVS (Annovis Bio) - Earnings growth in current year|Earnings per share growth this year GRCE (Grace Tx)|Earnings per share growth in current year Firefly Neuroscience Inc (AIFF)|anewmeds.com - Earnings per share growth this year|Earnings growth in current year NRSN (NeuroSense Therapeutics Ltd.)|revivapharma.com (RVPH) - Earnings per share growth rate in current year|MTVA: Net earnings per share growth this year|NRXS - Earnings growth in current year|heliusmedical.com (HSDT) - Earnings per share growth in current year|Passage Bio - Earnings per share increase in current year|Earnings per share growth in current year Neuphoria Therapeutics, Inc.|Earnings per share growth rate in current year minervaneurosciences.com NERV|Earnings growth in current year ATHA|Earnings growth in current year Addex Therapeutics Ltd. (ADXN)|Earnings growth in current year ALZN (Alzamend Neuro)|CYCN - Net earnings per share growth this year|Protagenic - Earnings growth in current year|KTTA - Earnings growth in current year|CRGT: Earnings growth in current year|Earnings per share growth this year ATXI|BCLI (Brainstorm Cell Therapeutics, Inc.) - Earnings growth in current year|Cara Therapeutics Inc (CARA) - Expected net earnings per share growth this year|Earnings growth in current year CHRO|Earnings growth in current year eliemtx.com (ELYM)|Intra-Cellular Therapies, Inc. - Net earnings per share growth this year|Earnings per share increase in current year LBPH|MRNS - Earnings per share growth in current year|Earnings per share trend in current year NKGN|NRBO: Earnings growth in current year|sagerx.com - Earnings per share increase in current year|SNPX (Synaptogenix) - Earnings growth in current year|Earnings growth in current year Trevena Inc.|Earnings per share growth in current year Vigil Neuroscience (VIGL)|WENA (anewmeds.com) - Earnings per share increase in current year|Earnings per share growth in current year Cerevel Therapeutics CERE
